Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.